ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / AEMD / earnings
NMTC (33) PLSM (47) FEMY (30) ICU (31) ⌘ Pro Terminal →

Aethlon Medical Inc. (AEMD) Next Earnings Date & Expected ±11.7% Move

$5.44 -1.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.42

Aethlon Medical Inc. (AEMD) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE D- • RED ALERT Cap $8.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AEMD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.44 (-1.45% 1D, market cap $8.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEMD ranks #580 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AEMD compare to NMTC and PLSM in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AEMD?
▼

Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $0 in revenue, -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.42 (-0.45%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510036
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (5)Whales (7)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
$28 Bull$5 Base$4 Bear
📬 FREE AEMD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AEMD)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY AEMD SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (25% of score)

FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 53.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
44
Grade D$5.58-4.8% Next Q
Q2 (-2Q)
41
Grade D$5.31-4.5% Next Q
Q3 (-1Q)
39
Grade E$5.07+7.3% Next Q
Current
36
Grade D-$5.44-8.3% Hist 90D α
Trajectory: D (44) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AEMD Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AEMD currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.58) and Max Pain ($5.71) forces dealer call-delta covering toward $27.51.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AEMD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AEMD Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 36%NO 64%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 29, 2026 (~56 DAYS)

Historical OHLCV Volatility ±11.7% Swing Band

±$0.64 Expected Swing
$4.80 (-11.7%)Spot $5.44$6.08 (+11.7%)
MODEL EARNINGS SETUP GAUGE

AEMD Quantitative Pre-Earnings Setup: 36/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (36/100)Model Risk Weight (64/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252026-03-31$0-$7.2M-$7.0M52%
FY 20242025-03-31$0-$13.4M-$7.6M52%
FY 20232024-03-31$0-$12.2M-$10.1M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AEMD)

  • ✓Walkthrough of AEMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AEMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.67%▼ DESCENDING CHANNEL
2026-11-03O $5.52H $5.52L $5.44C $5.44VOL 27.7K
RES: $6.79SUP: $0.22SMA50: $4.58SMA200: $7.69
$28.74$21.33$13.92$6.52$-0.89RES $6.79SUP $0.22$5.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AEMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AEMD Butterfly Map → + Track AEMD →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on AEMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AEMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AEMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AEMD)

Health Care Rank #580 of 1016 ⚔️ NMTC vs AEMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AEMD vs. NMTC, PLSM, FEMY, ICU)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aethlon Medical Inc. (AEMD) ranks #580 by composite RQD confidence (36/100, grade D-) and #905 by equity capitalization ($8.7M). Within this direct 5-issuer industry benchmark cohort, AEMD leads on earnings valuation at N/A trailing P/E, while AEMD leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PLSM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AEMD at 36/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AEMD ACTIVE
Aethlon Medical Inc.
D- 36/100 — — -35.0% -1.45% $8.7M Benchmark Subject
NMTC
NeuroOne Medical Technologies Corporation
E 33/100 — 56.5% -35.0% -4.39% $8.4M /nmtc-vs-aemd →
PLSM
Pulsenmore Ltd.
D 47/100 — — — +3.09% $10.9M /plsm-vs-aemd →
FEMY
Femasys Inc.
E 30/100 — 62.0% -35.0% +1.11% $11.5M /femy-vs-aemd →
ICU
SeaStar Medical Holding Corporation
E 31/100 — 95.7% -35.0% -3.03% $11.8M /icu-vs-aemd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0000882291

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Aethlon Medical Inc. (AEMD) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.2M, operating cash flow of -$7.0M, and free cash flow of -$7.0M (+8.4% YoY). On the balance sheet, AEMD closed FY2025 with $8.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $0 -$7.2M -$7.0M -$7.0M $8.1M —
FY2024 (FY) 2025-03-31 $0 -$13.4M -$7.6M -$7.6M $6.5M —
FY2023 (FY) 2024-03-31 $0 -$12.2M -$10.1M -$10.1M — —

3. AEMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AEMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aethlon Medical Inc. (NASDAQ: AEMD) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $5.44 (-1.45% 1D, market cap $8.7M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AEMD ranks #580 in composite RQD confidence.

How does AEMD compare to NMTC and PLSM in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), AEMD carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NMTC (NeuroOne Medical Technologies Corporation) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $8.4M) and PLSM (Pulsenmore Ltd.) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, AEMD leads on earnings multiple (N/A) while AEMD leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AEMD?

Per AEMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0000882291), Aethlon Medical Inc. generated $0 in revenue, -$7.2M in net income, and -$7.0M in free cash flow against $8.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AEMD trading relative to its 50-day, 200-day, and 52-week technical levels?

AEMD last traded at $5.44 (-1.45% on volume of 27,685 shares), positioning the stock +18.78% above its 50-day simple moving average ($4.58) and -29.26% below its 200-day simple moving average ($7.69). Across its 52-week range of $1.41 to $26.20, AEMD sits at the 16.3% percentile with a 14-day RSI of 53.2 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($4.80 to $6.08).

AEMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is AEMD's next earnings date?

Based on SEC filing cadence, Aethlon Medical Inc. (AEMD)'s next quarterly reporting window is estimated around Dec 29, 2026.

How much is AEMD stock expected to move on earnings?

Volatility modeling currently projects a ±11.7% event move for AEMD, spanning a range between $4.8 and $6.08.

Direct Sub-Reports: AEMD RQD Cockpit AEMD 12M Forecast AEMD Earnings & Move AEMD Dividends & DRIP AEMD Insiders & 13F AEMD Whale Options AEMD Profit Sankey AEMD News & Why
ROARABLE RATING BRIEF • RQD 36/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

AEMD — Aethlon Medical Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:09Z

Roarable Rating Brief: What This Means to a Prospective Investor

The Roarable RQD score is 38 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow" (per the Roarable RQD rating). Across its five pillars:

  • Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of 0%. For an investor, this means the business is not currently generating returns on capital or free cash flow; valuation cannot rest on earnings or cash yield.
  • Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar covers institutional accumulation and options positioning. The score is below midpoint, so institutional support signals are weak in the source data.
  • Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score indicates insider activity does not provide a strong conviction signal.
  • Macro Regime Fit: 9 / 20. Per the Roarable RQD rating, beta is 1.0 with sector sensitivity considered. A neutral beta combined with a low score means the stock offers no clear macro tailwind in the framework.
  • Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.5. This is the strongest pillar, but still sub-50%, indicating balance-sheet fragility.

Investor implications: the upside case depends on a turnaround in operating cash generation, which the current data does not show. The valuation tradeoff is that the stock trades at a $8.9M market capitalization with negative ROIC, so price action is not anchored by reported earnings. The low pillar scores in cash engine, flow, and insider conviction point to limited near-term confirmation for a recovery thesis. This is an analytical summary, not personalized advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-7.3M$-7.2MN/A$-7.0M$7.0MN/A
FY 2024$0.0M$-9.3M$-13.4MN/A$-7.6M$4.8MN/A
FY 2023$0.0M$-12.6M$-12.2MN/A$-10.1MN/AN/A

Per the SEC financials, the company reported no revenue and operating losses in each period shown, with gross, operating, and net margins all at 0% per the market data. Per the market data, ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with Debt/Equity of 0.5. Cash reported at $7.0M for FY 2025 compared with $4.8M for FY 2024, while operating losses narrowed from $-9.3M to $-7.3M over that span.

Open Questions

  • What specific products or revenue streams, if any, generate the company's income given $0.0M reported revenue?
  • What is the cash runway implied by FY 2025 cash of $7.0M against operating losses of $-7.3M?
  • What are the terms, size, and direction of the Form 4 transactions and the Jane Street subsidiary stake disclosures?
  • Why do market-cap figures differ between the profile ($0.0B) and market data ($8.9M), and which is correct?
  • What is the debt structure behind the reported Debt/Equity of 0.5 when debt is listed as N/A in every period?

AEMD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aethlon Medical Inc. (AEMD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AEMD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AEMD Bull vs. Bear Conversation Board — What's Your Call at $5.44?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AEMD 🐻 67% BEARISH CONVICTION
1. Pick Your Side on AEMD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $4.86 (-12.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is AEMD (D- • RQD 38/100) a Buy at $5.52?

Welcome to the AEMD (Aethlon Medical Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $4.20 (-23.9%)
Spot @ $5.52

Pump the brakes on AEMD — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on AEMD, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Aethlon Medical Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $6.46 (+17.0%)
Spot @ $5.52

AEMD cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on AEMD, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $5.52 (52-wk range $1.41 - $26.90), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%